CoChat

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Glucagon, an essential regulator of glucose homeostasis, also modulates lipid metabolism and promotes weight loss, as reflected by the wasting observed in glucagonoma patients. Recently, coagonist peptides that include glucagon agonism have emerged as promising therapeutic candidates for the treatment of obesity and diabetes. We developed a novel stable and soluble glucagon receptor (GcgR) agonist, which allowed for in vivo dissection of glucagon action. As expected, chronic GcgR agonism in mice resulted in hyperglycemia and lower body fat and plasma cholesterol. Notably, GcgR activation also raised hepatic expression and circulating levels of fibroblast growth factor 21 (FGF21). This effect was retained in isolated primary hepatocytes from wild-type (WT) mice, but not GcgR knockout mice. We confirmed this link in healthy human volunteers, where injection of natural glucagon increased plasma FGF21 within hours. Functional relevance was evidenced in mice with genetic deletion of FGF21, where GcgR activation failed to induce the body weight loss and lipid metabolism changes observed in WT mice. Taken together, these data reveal for the first time that glucagon controls glucose, energy, and lipid metabolism at least in part via FGF21-dependent pathways.

Overview

Integrity signals

Registry

Crossref · 10.2337/db12-1116

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

FIG. 1. Characteristics of the GcgR agonist IUB288. A: IUB288 chemical structure. Activity of IUB288 at the GcgR (B) and GLP-1 receptor (C) in cultured HEK293 cells. Dose-normalized bioavailability of IUB288 (D) after a single subcutaneous injection (10 nmol/kg) in C57Bl/6J mice (displayed as the mean of n = 2). Blood glucose excursion (E) in response to an acute IUB288 challenge (10 nmol/kg) in lean, chow-fed, male C57Bl/6J mice (n = 8 per treatment). All data are represented as mean ± SEM. ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis.
FIG. 1. Characteristics of the GcgR agonist IUB288. A: IUB288 chemical structure. Activity of IUB288 at the GcgR (B) and GLP-1 receptor (C) in cultured HEK293 cells. Dose-normalized bioavailability of IUB288 (D) after a single subcutaneous injection (10 nmol/kg) in C57Bl/6J mice (displayed as the mean of n = 2). Blood glucose excursion (E) in response to an acute IUB288 challenge (10 nmol/kg) in lean, chow-fed, male C57Bl/6J mice (n = 8 per treatment). All data are represented as mean ± SEM. ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis.CC BY-NC-ND · PubMed Central
FIG. 2. Dose-dependency study of chronic GcgR activation. Body weight (A), food intake (B), and ad libitum blood glucose (C and D) in response to vehicle (PBS, ○) or 0.3 (●), 1.0 (□), 3.0 (■), or 10 nmol/kg/day (△) IUB288. All treatments were conducted in 11-month-old male C57Bl/6J mice maintained on HFD for 9 months. All data are represented as mean ± SEM; n = 8 per treatment. **P < 0.01; ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis. Lowercase letters (D) denote statistically similar (P > 0.05) groups, one-way ANOVA with Bonferroni post hoc analysis.
FIG. 2. Dose-dependency study of chronic GcgR activation. Body weight (A), food intake (B), and ad libitum blood glucose (C and D) in response to vehicle (PBS, ○) or 0.3 (●), 1.0 (□), 3.0 (■), or 10 nmol/kg/day (△) IUB288. All treatments were conducted in 11-month-old male C57Bl/6J mice maintained on HFD for 9 months. All data are represented as mean ± SEM; n = 8 per treatment. **P < 0.01; ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis. Lowercase letters (D) denote statistically similar (P > 0.05) groups, one-way ANOVA with Bonferroni post hoc analysis.CC BY-NC-ND · PubMed Central
FIG. 3. Effects of chronic GcgR activation on energy balance and plasma lipids. Body weight (A), fat mass (B), and food intake (C) in response to 16 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment in standard chow– (circles) or HFD-fed (squares) C57Bl/6J mice. Plasma concentrations of triglycerides (D) and cholesterol (E) and hepatic HMGCR expression (F) after 18 days of vehicle (PBS, closed bars) or 10 nmol/kg/day IUB288 (open bars) in standard chow– or HFD-fed C57Bl/6J mice. All treatments were conducted in 11-month-old male C57Bl/6J mice maintained on standard chow or HFD for 9 months. All data are represented as mean ± SEM; n = 8 per treatment. A–C: *P < 0.05; ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis. D and E: ***P < 0.001 vs. vehicle control, one-way ANOVA with Bonferroni post hoc analysis. F: *P < 0.05 vs. vehicle control, unpaired Student t test.
FIG. 3. Effects of chronic GcgR activation on energy balance and plasma lipids. Body weight (A), fat mass (B), and food intake (C) in response to 16 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment in standard chow– (circles) or HFD-fed (squares) C57Bl/6J mice. Plasma concentrations of triglycerides (D) and cholesterol (E) and hepatic HMGCR expression (F) after 18 days of vehicle (PBS, closed bars) or 10 nmol/kg/day IUB288 (open bars) in standard chow– or HFD-fed C57Bl/6J mice. All treatments were conducted in 11-month-old male C57Bl/6J mice maintained on standard chow or HFD for 9 months. All data are represented as mean ± SEM; n = 8 per treatment. A–C: *P < 0.05; ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis. D and E: ***P < 0.001 vs. vehicle control, one-way ANOVA with Bonferroni post hoc analysis. F: *P < 0.05 vs. vehicle control, unpaired Student t test.CC BY-NC-ND · PubMed Central
FIG. 4. Effects of chronic GcgR activation in db/db mice. Absolute (A) and relative body weight (B) of db/db mice during 7 days of vehicle (PBS, ■) or 10 nmol/kg/day IUB288 (□) treatment. Body core temperature (C) on day 6 of vehicle (PBS, ■) or 10 nmol/kg/day IUB288 (□). Ad libitum blood glucose during chronic GcgR activation (D). Fasting blood glucose (6 h) (E) of db/db mice after 7 days of chronic GcgR activation. Blood glucose excursion (F) and rate of disappearance (Kd, 0–45 min) during 0.75 units/kg insulin challenge (G) after 7 days of chronic GcgR activation in 6-h fasted db/db mice. Cumulative food intake (H) of db/db mice (three cages of four mice per cage) during 7 days of vehicle (PBS, ■) or 10 nmol/kg/day IUB288 (open squares) treatment. All treatments were conducted in 12-week-old male db/db mice maintained on standard chow diet. All data are represented as mean ± SEM; n = 11–12 per treatment. A, B, and F: *P < 0.05; ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis. C: **P < 0.01 vs. vehicle control, unpaired Student t test.
FIG. 4. Effects of chronic GcgR activation in db/db mice. Absolute (A) and relative body weight (B) of db/db mice during 7 days of vehicle (PBS, ■) or 10 nmol/kg/day IUB288 (□) treatment. Body core temperature (C) on day 6 of vehicle (PBS, ■) or 10 nmol/kg/day IUB288 (□). Ad libitum blood glucose during chronic GcgR activation (D). Fasting blood glucose (6 h) (E) of db/db mice after 7 days of chronic GcgR activation. Blood glucose excursion (F) and rate of disappearance (Kd, 0–45 min) during 0.75 units/kg insulin challenge (G) after 7 days of chronic GcgR activation in 6-h fasted db/db mice. Cumulative food intake (H) of db/db mice (three cages of four mice per cage) during 7 days of vehicle (PBS, ■) or 10 nmol/kg/day IUB288 (open squares) treatment. All treatments were conducted in 12-week-old male db/db mice maintained on standard chow diet. All data are represented as mean ± SEM; n = 11–12 per treatment. A, B, and F: *P < 0.05; ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis. C: **P < 0.01 vs. vehicle control, unpaired Student t test.CC BY-NC-ND · PubMed Central
FIG. 5. Glucagon as an FGF21 secretagogue. Plasma FGF21 concentration (A) in response to acute GcgR activation (n = 8; 10 nmol/kg IUB288). Hepatic FGF21 expression (B) and plasma FGF21 concentration (C) after 18 days of vehicle (PBS, closed bars) or 10 nmol/kg/day IUB288 (open bars) in 2-h fasted, HFD-fed mice (n = 4–5). Relative FGF21 expression (D) and secretion (E) in isolated primary hepatocytes from WT and GcgR knockout (GcgR−/−) mice after 9.5 and 25 h glucagon treatment, respectively. Relative FGF21 expression in cultured H4IIE cells (F) after 120 min GcgR activation (0.133 nmol/mL IUB288). Plasma FGF21 concentration (G) and area under the curve (AUC) analysis (H) after glucagon challenge (1 mg) in human subjects. Data from A–C obtained in 11-month-old male C57Bl/6J mice maintained on HFD for 9 months. All data are represented as mean ± SEM. A and G: *P < 0.05; **P < 0.01; ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis. B, C, F, and H: *P < 0.05; ***P < 0.001 vs. vehicle control, unpaired Student t test. D and E: Sigmoidal dose-response best fit (with variable slope).
FIG. 5. Glucagon as an FGF21 secretagogue. Plasma FGF21 concentration (A) in response to acute GcgR activation (n = 8; 10 nmol/kg IUB288). Hepatic FGF21 expression (B) and plasma FGF21 concentration (C) after 18 days of vehicle (PBS, closed bars) or 10 nmol/kg/day IUB288 (open bars) in 2-h fasted, HFD-fed mice (n = 4–5). Relative FGF21 expression (D) and secretion (E) in isolated primary hepatocytes from WT and GcgR knockout (GcgR−/−) mice after 9.5 and 25 h glucagon treatment, respectively. Relative FGF21 expression in cultured H4IIE cells (F) after 120 min GcgR activation (0.133 nmol/mL IUB288). Plasma FGF21 concentration (G) and area under the curve (AUC) analysis (H) after glucagon challenge (1 mg) in human subjects. Data from A–C obtained in 11-month-old male C57Bl/6J mice maintained on HFD for 9 months. All data are represented as mean ± SEM. A and G: *P < 0.05; **P < 0.01; ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis. B, C, F, and H: *P < 0.05; ***P < 0.001 vs. vehicle control, unpaired Student t test. D and E: Sigmoidal dose-response best fit (with variable slope).CC BY-NC-ND · PubMed Central
FIG. 6. Energy balance during chronic GcgR activation in FGF21−/− mice. Body weight, fat mass, lean mass, and food intake of WT (A, C, E, and G) and FGF21−/− (B, D, F, and H) mice during 20 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment. All treatments were conducted in 12-week-old male littermates maintained on standard chow diet until day 0 and then switched to HFD upon initiation of GcgR activation. All data are represented as mean ± SEM; n = 12–16. *P < 0.05; **P < 0.01; ***P < 0.001 vs. genotype-specific vehicle control, two-way ANOVA with Bonferroni post hoc analysis.
FIG. 6. Energy balance during chronic GcgR activation in FGF21−/− mice. Body weight, fat mass, lean mass, and food intake of WT (A, C, E, and G) and FGF21−/− (B, D, F, and H) mice during 20 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment. All treatments were conducted in 12-week-old male littermates maintained on standard chow diet until day 0 and then switched to HFD upon initiation of GcgR activation. All data are represented as mean ± SEM; n = 12–16. *P < 0.05; **P < 0.01; ***P < 0.001 vs. genotype-specific vehicle control, two-way ANOVA with Bonferroni post hoc analysis.CC BY-NC-ND · PubMed Central
FIG. 7. EE during chronic GcgR activation. Dynamic and cumulative EE and locomotor activity of WT (A, C, and E) and FGF21−/− (B, D, and F) mice during 72 h of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment. All treatments were conducted in 12-week-old male littermates maintained on standard chow diet. IUB288 or vehicle administered daily, 2 h prior to dark phase. P values of A–C denote main effect of treatment vs. vehicle control by two-way ANOVA. All data are represented as mean ± SEM; n = 6. E: **P < 0.01 vs. genotype-specific vehicle control, two-way ANOVA with Bonferroni post hoc analysis.
FIG. 7. EE during chronic GcgR activation. Dynamic and cumulative EE and locomotor activity of WT (A, C, and E) and FGF21−/− (B, D, and F) mice during 72 h of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment. All treatments were conducted in 12-week-old male littermates maintained on standard chow diet. IUB288 or vehicle administered daily, 2 h prior to dark phase. P values of A–C denote main effect of treatment vs. vehicle control by two-way ANOVA. All data are represented as mean ± SEM; n = 6. E: **P < 0.01 vs. genotype-specific vehicle control, two-way ANOVA with Bonferroni post hoc analysis.CC BY-NC-ND · PubMed Central
FIG. 8. Lipidemia and glycemia during chronic GcgR activation. Liver triglyceride (B) and plasma cholesterol (A), triglyceride (C), and NEFA (D) concentrations of WT and FGF21−/− mice after 20 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment (n = 4–6). Ad libitum blood glucose (E) of WT and FGF21−/− mice on day 19. Glucose tolerance (F) (as assessed by 1.5 g/kg intraperitoneal glucose challenge) and area under the curve analysis (G) of WT (squares) and FGF21−/− (circles) mice after 19 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment (n = 12–16). All treatments conducted in 12-week-old male littermates maintained on standard chow diet until day 0 and then switched to HFD upon initiation of GcgR activation. All data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 vs. genotype-specific vehicle control, two-way ANOVA with Bonferroni post hoc analysis. F: **P < 0.01; ***P < 0.001 vs. WT vehicle control, two-way ANOVA with Bonferroni post hoc analysis.
FIG. 8. Lipidemia and glycemia during chronic GcgR activation. Liver triglyceride (B) and plasma cholesterol (A), triglyceride (C), and NEFA (D) concentrations of WT and FGF21−/− mice after 20 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment (n = 4–6). Ad libitum blood glucose (E) of WT and FGF21−/− mice on day 19. Glucose tolerance (F) (as assessed by 1.5 g/kg intraperitoneal glucose challenge) and area under the curve analysis (G) of WT (squares) and FGF21−/− (circles) mice after 19 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment (n = 12–16). All treatments conducted in 12-week-old male littermates maintained on standard chow diet until day 0 and then switched to HFD upon initiation of GcgR activation. All data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 vs. genotype-specific vehicle control, two-way ANOVA with Bonferroni post hoc analysis. F: **P < 0.01; ***P < 0.001 vs. WT vehicle control, two-way ANOVA with Bonferroni post hoc analysis.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 38 references

Cited by

See all 245

Metadata

Authors
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., Krishna, R., Arafat, A. M., Konkar, A., Belli, S., Kapps, M., Woods, S. C., Hofmann, S. M., D’Alessio, D., Pfluger, P. T., Perez-Tilve, D., Seeley, R. J., Konishi, M., Itoh, N., Kharitonenkov, A., Spranger, J., DiMarchi, R. D., & Tschöp, M. H.
Affiliations
  • University of Cincinnati (US)
  • Helmholtz Munich (DE)
  • Eli Lilly (United States) (US)
  • Indiana University Bloomington (US)
  • Charité – Universitätsmedizin Berlin (DE)
  • F. Hoffmann-La Roche AG (CH)
  • Metabolic Disease Institute, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio
  • Kyoto University (JP)
Corresponding author
Tschöp, Matthias H.
Venue
Diabetes
Published
2013-04-16
Volume
62
Issue
5
Pages
1453-1463
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2131192628
Cited by
245
References
38
Citations by year
2026: 10 · 2025: 13 · 2024: 21 · 2023: 15 · 2022: 17 · 2021: 19 · 2020: 16 · 2019: 16 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 27 · 2014: 22 · 2013: 12
FWCI
12.40
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • OPUS (Augsburg University) (submittedVersion, cc-by-nc-nd)
Funders
  • American Diabetes Association
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • University of Cincinnati
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
FGF21, glucagon, glucagon receptor agonist, glucose homeostasis, lipid metabolism, weight loss, hyperglycemia, obesity, serum cholesterol, energy metabolism
MeSH terms
Adult, Animals, Cells, Cultured, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Fibroblast Growth Factors, Glucagon, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Mice, Mutant Strains, Obesity, Peptides, Recombinant Proteins, Receptors, Glucagon, Mice, Knockout, Cross-Over Studies, Anti-Obesity Agents, Hepatocytes, Mice, Rats, HEK293 Cells, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions. https://app.cochat.ai/papers/10.2337/db12-1116
The paper
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., Krishna, R., Arafat, A. M., Konkar, A., Belli, S., Kapps, M., Woods, S. C., Hofmann, S. M., D’Alessio, D., Pfluger, P. T., . . . Tschöp, M. H. (2013). Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions. Diabetes. https://doi.org/10.2337/db12-1116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.